Astellas Pharma (ALPMY) announced that it has entered into an agreement with Roche Diabetes Care Japan Co., Ltd. (RHHBY) for the development and commercialization of Roche Diabetes Care’s world-renowned Accu-Chek Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar. BlueStar is an FDA-cleared digital health solution for diabetes patients, developed by Welldoc, Inc. and is currently marketed in the U.S. and Canada. Astellas and Welldoc are jointly developing BlueStar in Japan. In the future, Astellas will aim to obtain regulatory approval and reimbursement as a combined medical product.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- Roche downgraded to Equal Weight from Overweight at Barclays
- Roche to collaborate with Lilly on early diagnosis of Alzheimer’s disease
- Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer’s disease
- Genentech announces long-term data for Evrysdi in SUNFISH study
- New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
